Basic Information
| Drug ID | DDPD00220 |
|
| Drug Name | Nelfinavir | |
| Molecular Weight | 567.782 | |
| Molecular Formula | C32H45N3O4S | |
| CAS Number | 159989-64-7 | |
| SMILES | [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C | |
| External Links | ||
| DRUGBANK | DB00220 | |
| PubChem Compound | 64143 | |
| PDR | 1821 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 6.0 | - | 6.0 | - | DRUGBANK |
| Melting Point | 349.84 | ℃ | 349.84 | ℃ | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 50.0 | % | 20-80 | % | PO, oral; food; AIDS,HIV; | The Pharmacological Basis of Therapeutics | |
| C Max | 3200.0 | ng/ml | 3.2±1.2 | mcg/ml | adults; AIDS,HIV; | The Pharmacological Basis of Therapeutics | |
| T Max | 3.0 | h | 3.0±1.1 | h | adults; AIDS,HIV; | The Pharmacological Basis of Therapeutics | |
| Clearance | 0.72 | L/h/kg | 12.0±7.2 | ml/min/kg | apparent clearance; normal,healthy; patients; | Children ↑ ; | The Pharmacological Basis of Therapeutics |
| Volume of Distribution | 4.5 | L/kg | 2.0-7 | L/kg | DRUGBANK | ||
| Volume of Distribution | 4.5 | L/kg | 2-7 | L/kg | Apparent volume of distribution; normal,healthy; patients; | The Pharmacological Basis of Therapeutics | |
| Half-life | 4.3 | h | 3.5-5 | h | DRUGBANK | ||
| Half-life | 4.0 | h | 3-5 | h | PO, oral; | The Pharmacological Basis of Therapeutics | |
| Toxicity LD50 | 5000.0 | mg/kg | >5 | g/kg | PO, oral; Rattus, Rat; | DRUGBANK | |
| Eliminate Route | 87.0 | % | 87 | % | Faeces excretion; PO, oral; | DRUGBANK | |
| Eliminate Route | 1.5 | % | 1-2 | % | Urinary excretion; PO, oral; | DRUGBANK | |
| Eliminate Route | 22.0 | % | 22 | % | Faeces excretion; PO, oral; Unchanged drug; | DRUGBANK | |
| Eliminate Route | 1.5 | % | 1-2 | % | Urinary excretion; normal,healthy; AIDS,HIV; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 98.0 | % | 98 | % | DRUGBANK | ||
| Protein Binding | 98.5 | % | 98-99 | % | normal,healthy; AIDS,HIV; human, homo sapiens; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 110.0 | mg/kg/day | 110 | mg/kg/day | PO, oral | Viracept | nelfinavir mesylate | PDR |
| Max dose for children | 2500.0 | mg/day | 2500 | mg/day | PO, oral | Viracept | nelfinavir mesylate | PDR |
| Max dose for adolescents | 2500.0 | mg/day | 2500 | mg/day | PO, oral | Viracept | nelfinavir mesylate | PDR |
| Max dose for adults | 2500.0 | mg/day | 2500 | mg/day | PO, oral | Viracept | nelfinavir mesylate | PDR |
| Max dose for geriatric | 2500.0 | mg/day | 2500 | mg/day | PO, oral | Viracept | nelfinavir mesylate | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1